{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T20:55:13Z","timestamp":1770843313857,"version":"3.50.1"},"reference-count":31,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Low-density lipoprotein (LDL) receptor-related protein-associated protein 1 (LRPAP1) had been identified by B-cell receptor (BCR) expression cloning and subsequent protein array screening as a frequent and proliferation-inducing autoantigen of mantle cell lymphoma (MCL). Of interest, high-titered and light chain\u2013restricted LRPAP1 autoantibodies were detected in 8 of 28 patients with MCL. In the present study, LRPAP1 autoantibodies in sera of patients treated within the Younger and Elderly trials of the European MCL Network were analyzed regarding frequency, association with disease characteristics, and prognostic impact. LRPAP1 autoantibodies were detected in 41 (13%) of 312 evaluable patients with MCL. These LRPAP1 autoantibodies belonged predominantly to the immunoglobulin G (IgG) class and were clonally light chain restricted (27 with\u00a0\u03ba\u00a0light chains, 14 patients with\u00a0\u03bb\u00a0light chains). Titers ranged between 1:400 and 1:3200. The presence of LRPAP1 autoantibodies was not significantly associated with any baseline clinical characteristic, however, it was associated with a superior 5-year probability for failure-free survival (FFS) of 70% (95% confidence interval [CI], 57% to 87%) vs 51% (95% CI, 44% to 58%),\u00a0P = .0052; and for overall survival (OS) of 93% (95% CI, 85% to 100%) vs 68% (95% CI, 62% to 74%),\u00a0P\u00a0= .0142. LRPAP1-seropositive patients had a Mantle Cell Lymphoma International Prognostic Index\u2013adjusted hazard ratio for FFS of\u00a00.48 (95% CI 0.27-0.83, P = .0083)\u00a0and for OS of\u00a00.47 (95% CI 0.24-0.94, P = .032). LRPAP1 autoantibodies were frequently detected in a large cohort of MCL patients treated within prospective multicenter clinical trials. Our results suggest better outcomes for LRPAP1-autoantibody seropositive patients.<\/jats:p>","DOI":"10.1182\/blood.2020008835","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T22:05:14Z","timestamp":1611957914000},"page":"3251-3258","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8167-2989","authenticated-orcid":false,"given":"Lorenz","family":"Thurner","sequence":"first","affiliation":[{"name":"Saarland University Medical School, Jos\u00e9 Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Homburg\/Saar, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Fadle","sequence":"additional","affiliation":[{"name":"Saarland University Medical School, Jos\u00e9 Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Homburg\/Saar, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg Thomas","family":"Bittenbring","sequence":"additional","affiliation":[{"name":"Saarland University Medical School, Jos\u00e9 Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Homburg\/Saar, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evi","family":"Regitz","sequence":"additional","affiliation":[{"name":"Saarland University Medical School, Jos\u00e9 Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Homburg\/Saar, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Schuck","sequence":"additional","affiliation":[{"name":"Saarland University Medical School, Jos\u00e9 Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Homburg\/Saar, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onur","family":"Cetin","sequence":"additional","affiliation":[{"name":"Saarland University Medical School, Jos\u00e9 Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Homburg\/Saar, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariane","family":"Stuhr","sequence":"additional","affiliation":[{"name":"H\u00f4pital Necker, Institut Imagine, Assistance Publique\u2013H\u00f4pitaux de Paris, University Paris Descartes, Paris, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1417-7571","authenticated-orcid":false,"given":"Torben","family":"Rixecker","sequence":"additional","affiliation":[{"name":"Saarland University Medical School, Jos\u00e9 Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Homburg\/Saar, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Murawski","sequence":"additional","affiliation":[{"name":"Saarland University Medical School, Jos\u00e9 Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Homburg\/Saar, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viola","family":"Poeschel","sequence":"additional","affiliation":[{"name":"Saarland University Medical School, Jos\u00e9 Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Homburg\/Saar, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8832-252X","authenticated-orcid":false,"given":"Dominic","family":"Kaddu-Mulindwa","sequence":"additional","affiliation":[{"name":"Saarland University Medical School, Jos\u00e9 Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Homburg\/Saar, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus-Dieter","family":"Preuss","sequence":"additional","affiliation":[{"name":"Saarland University Medical School, Jos\u00e9 Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Homburg\/Saar, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Stilgenbauer","sequence":"additional","affiliation":[{"name":"Saarland University Medical School, Jos\u00e9 Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Homburg\/Saar, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[{"name":"H\u00f4pital Necker, Institut Imagine, Assistance Publique\u2013H\u00f4pitaux de Paris, University Paris Descartes, Paris, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2617-9427","authenticated-orcid":false,"given":"Hanneke C.","family":"Kluin-Nelemans","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, Department of Hematology, University of Groningen, Groningen, The Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Dr. Senckenberg Institute of Pathology, Goethe University Hospital of Frankfurt am Main, Frankfurt am Main, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Department of Medicine III, LMU Hospital, Munich, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Pott","sequence":"additional","affiliation":[{"name":"Second Department of Medicine, University Hospital Schleswig-Holstein, Kiel, Germany; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritz","family":"Bewarder","sequence":"additional","affiliation":[{"name":"Saarland University Medical School, Jos\u00e9 Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Homburg\/Saar, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0749-1389","authenticated-orcid":false,"given":"Eva","family":"Hoster","sequence":"additional","affiliation":[{"name":"Department of Medicine III, LMU Hospital, Munich, Germany;"},{"name":"Institute for Medical Information Processing, Biometry, and Epidemiology, Ludwig Maximilian University, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"issue":"20","key":"2021062208221557600_B1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2021062208221557600_B2","first-page":"181","article-title":"Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse","volume":"113","author":"Swerdlow","year":"1983","journal-title":"Am J Pathol"},{"issue":"1","key":"2021062208221557600_B3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","article-title":"Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network","volume":"131","author":"Tiemann","year":"2005","journal-title":"Br J Haematol"},{"issue":"7","key":"2021062208221557600_B4","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood.V76.7.1387.1387","article-title":"Genotypic characterization of centrocytic lymphoma: frequent rearrangement of the chromosome 11 bcl-1 locus","volume":"76","author":"Williams","year":"1990","journal-title":"Blood"},{"issue":"5","key":"2021062208221557600_B5","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.ccell.2016.09.014","article-title":"Decoding the DNA methylome of mantle cell lymphoma in the light of the entire B cell lineage","volume":"30","author":"Queir\u00f3s","year":"2016","journal-title":"Cancer Cell"},{"issue":"8","key":"2021062208221557600_B6","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1182\/blood-2003-05-1383","article-title":"VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome","volume":"102","author":"Kienle","year":"2003","journal-title":"Blood"},{"issue":"11","key":"2021062208221557600_B7","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1182\/blood-2011-03-343434","article-title":"Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases","volume":"118","author":"Hadzidimitriou","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2021062208221557600_B8","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2002-11-3479","article-title":"Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma","volume":"101","author":"Walsh","year":"2003","journal-title":"Blood"},{"issue":"1","key":"2021062208221557600_B9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2015-11-681460","article-title":"Pathogenic role of B-cell receptor signaling and canonical NF-\u03baB activation in mantle cell lymphoma","volume":"128","author":"Saba","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2021062208221557600_B10","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2016-05-718494","article-title":"Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling","volume":"129","author":"Myklebust","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2021062208221557600_B11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"22","key":"2021062208221557600_B12","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3K\u03b4 inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"issue":"10020","key":"2021062208221557600_B13","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"issue":"13","key":"2021062208221557600_B14","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2021062208221557600_B15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41375-018-0182-1","article-title":"LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting","volume":"33","author":"Thurner","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"2021062208221557600_B16","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1006\/geno.1994.1348","article-title":"Chromosomal localization of human genes for the LDL receptor family member glycoprotein 330 (LRP2) and its associated protein RAP (LRPAP1)","volume":"22","author":"Korenberg","year":"1994","journal-title":"Genomics"},{"issue":"31","key":"2021062208221557600_B17","doi-asserted-by":"crossref","first-page":"21232","DOI":"10.1016\/S0021-9258(18)54845-6","article-title":"39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein\/alpha 2-macroglobulin receptor","volume":"266","author":"Herz","year":"1991","journal-title":"J Biol Chem"},{"issue":"13","key":"2021062208221557600_B18","doi-asserted-by":"crossref","first-page":"9035","DOI":"10.1016\/S0021-9258(19)50384-2","article-title":"A novel mechanism for controlling the activity of alpha 2-macroglobulin receptor\/low density lipoprotein receptor-related protein. Multiple regulatory sites for 39-kDa receptor-associated protein","volume":"267","author":"Williams","year":"1992","journal-title":"J Biol Chem"},{"issue":"20","key":"2021062208221557600_B19","doi-asserted-by":"crossref","first-page":"13364","DOI":"10.1016\/S0021-9258(18)98848-4","article-title":"Primary structure of alpha 2-macroglobulin receptor-associated protein. Human homologue of a Heymann nephritis antigen","volume":"266","author":"Strickland","year":"1991","journal-title":"J Biol Chem"},{"issue":"8","key":"2021062208221557600_B20","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1073\/pnas.91.8.3161","article-title":"Functional domains of the receptor-associated protein (RAP)","volume":"91","author":"Orlando","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"issue":"21","key":"2021062208221557600_B21","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.965.965","article-title":"R-CHOP\/R-DHAP compared to R-CHOP induction followed by high dose therapy with autologous stem cell transplantation induces higher rates of molecular remission in MCL: results of the MCL Younger Intergroup Trial of the European MCL Network [abstract]","volume":"116","author":"Pott","year":"2010","journal-title":"Blood"},{"issue":"21","key":"2021062208221557600_B22","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.965.965","article-title":"R-CHOP\/R-DHAP compared to R-CHOP induction followed by high dose therapy with autologous stem cell transplantation induces higher rates of molecular remission in MCL: results of the MCL Younger Intergroup Trial of the European MCL Network [abstract]","volume":"116","author":"Pott","year":"2010","journal-title":"Blood"},{"issue":"10044","key":"2021062208221557600_B23","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"2021062208221557600_B24","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"2021062208221557600_B25","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"17","key":"2021062208221557600_B26","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"S2","key":"2021062208221557600_B27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/hon.2437_129","article-title":"P53 but not SOX11 IHC has prognostic value independent of MIPI and KI-67 in prospective trials of the European-MCL Network","volume":"35","author":"Aukema","year":"2017","journal-title":"Hematol. Oncol"},{"issue":"suppl 1","key":"2021062208221557600_B28","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1182\/blood-2019-130068","article-title":"Clinical outcome of mantle cell lymphoma patients with high risk biology (high Ki-67, blastoid MCL, or high p53 expression) [abstract]","volume":"134","author":"Dreyling","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2021062208221557600_B29","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma","volume":"70","author":"Fern\u00e0ndez","year":"2010","journal-title":"Cancer Res"},{"issue":"18","key":"2021062208221557600_B30","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1182\/blood-2011-12-400580","article-title":"Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma","volume":"119","author":"Nygren","year":"2012","journal-title":"Blood"},{"issue":"suppl 15","key":"2021062208221557600_B31","article-title":"ZUMA-2: phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed\/refractory mantle cell lymphoma [abstract]","volume":"36","author":"Wang","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/23\/3251\/1810563\/bloodbld2020008835.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/23\/3251\/1810563\/bloodbld2020008835.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T08:24:02Z","timestamp":1624350242000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/23\/3251\/475090\/LRPAP1-autoantibodies-in-mantle-cell-lymphoma-are"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":31,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2021,1,29]]},"published-print":{"date-parts":[[2021,6,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020008835","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,29]]}}}